Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Cephalon is paying $20 million in up-front financing to Acusphere for an exclusive worldwide license to AI-525, a preclinical-stage injectable form of the anti-inflammatory drug celecoxib, which is the active ingredient in Pfizer's Celebrex. The formulation uses Acusphere's drug delivery technology for hydrophobic drugs. The deal includes a $15 million milestone payment and royalties on sales if AI-525, which targets postoperative pain relief, is approved. Cephalon also has an option to license Acusphere's Imagify, a cardiovascular imaging agent based on perflubutane-containing polymer microspheres. If exercised, Cephalon would pay Acusphere $40 million upon FDA approval of Imagify, as well as royalties.
This article has been sent to the following recipient: